Advocacy intelligence hub — real-time data for patient organizations
University of Washington — NA
Santa Catarina Federal University
Sohag University
KORU Medical Systems, Inc. — NA
ANRS, Emerging Infectious Diseases
Virchow Group — PHASE3
Children's Hospital of Philadelphia — PHASE1, PHASE2
Takeda
AIDS Malignancy Consortium — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Travel grants
Patient Assistance Programs1
Gamimune N
Bayer Corporation
Travel Grants4
Accessia Health Primary Immune Deficiency - Public Insurance Financial Assistance
Accessia Health
Immune Deficiency Foundation Manufacturer Copay Assistance Programs
Immune Deficiency Foundation
Immune Deficiency Foundation Other Support Resources
Immune Deficiency Foundation
Primary Immunodeficiency Financial Assistance Program
The Assistance Fund
Gamimune N
(Immune globulin intravenous, human)Orphan drugstandardBayer Corporation
Human Immunoglobulin G [EPC]
12.1 Mechanism of Action BIVIGAM is a replacement therapy in patients with primary humoral immunodeficiency (PI) (e.g. agammaglobulinaemia, hypogammag...
Robert Yarchoan, M.D.
National Cancer Institute (NCI)
📍 Bethesda, Maryland
Paul Szabolcs, MD
UPMC Children's Hospital of Pittsburgh
📍 Pittsburgh, Pennsylvania
Program Director, Clinical R&D
CSL Behring
Chiara Azzari
Azienda Ospedaliero-Universitaria Ospedale Pediatrico Meyer - Italy
📍 San Francisco, California
Timothy Olson, MD, PhD
Children's Hospital of Philadelphia
Mitchell Cairo, MD, MD
New York Medical College
📍 HAWTHORNE, NY